Enrolling by invitationPhase 3NCT03584165

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

Studying Choroideremia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
NightstaRx Ltd, a Biogen Company
Principal Investigator
Medical Director
Biogen
Intervention
BIIB111(genetic)
Enrollment
330 enrolled
Eligibility
18 years · MALE
Timeline
20182026

Study locations (25)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03584165 on ClinicalTrials.gov

Other trials for Choroideremia

Additional recruiting or active studies for the same condition.

See all trials for Choroideremia

← Back to all trials